Simulations Plus (SLP) has entered into a collaboration agreement with a pharmaceutical company to add a transdermal and subcutaneous dosing model within its GastroPlus simulation software program.
The pharmaceutical company will fund transdermal and subcutaneous drug absorption model in GastroPlus.
Simulations Plus chairman and chief executive officer Walt Woltosz said the funded collaboration will extend and enhance the GastroPlus simulation model for drug dosing via transdermal and subcutaneous dosing through a variety of dosage forms.
"Our funded collaborations enable us to extend the competitive advantage of GastroPlus without the need for Simulations Plus to fund the development directly," Woltosz added.
"These will include skin creams, patches, and microneedles for dosing through the skin, as well as injections below the skin in the subcutaneous model."
